We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Osimertinib plus Savolitinib Promising for Non-Small-Cell Lung Cancer with MET-Driven Resistance.
- Authors
Starr, Phoebe
- Abstract
The article focuses on combination of the investigational MET inhibitor savolitinib plus the EGFR inhibitor osimertinib achieved encouraging responses in patients with MET-amplified, EGFR-positive non–small-cell lung cancer (NSCLC). It mentions targeted therapy for lung cancer patients with EGFR mutations has consisted solely of monotherapy with various tyrosine kinase inhibitors. It also mentions combination showed encouraging antitumor activity in EGFR-mutant patients with MET amplification.
- Subjects
NON-small-cell lung carcinoma; FLUORESCENCE in situ hybridization
- Publication
Oncology Practice Management, 2019, Vol 9, Issue 7, p28
- ISSN
2164-4403
- Publication type
Article